Taking peoplePhase 1
Tests INR731 alone or with an ARPI in men with prostate cancer
Tests INR731, alone or with an ARPI, in men with metastatic castration resistant prostate cancer.
Key facts
- Who runs it
- Novartis Pharma AG
- Where
- Milan, ItalySee the siteAlso in 3 other countries, 5 sites
- Trial code
- Registry title
- A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 26 people, planned
- Started
- 8 Oct 2026
- Expected to end
- 24 Oct 2030
- Type of study
- Interventional
- Record updated
- 23 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with metastatic castration resistant prostate cancer. It studies INR731 alone or with an androgen receptor pathway inhibitor (ARPI).
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Metastatic castration resistant prostate cancer
Where in Italy
Also in 3 other countries, 5 sites
- ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests INR731 alone or with an ARPI in men with prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 23 October 2026